Editas Medicine, Inc. (EDIT)
2.17
+0.03
(+1.40%)
USD |
NASDAQ |
Nov 13, 16:00
2.165
0.00 (0.00%)
After-Hours: 19:59
Editas Medicine Profit Margin (Quarterly) : -225.7% for Sept. 30, 2026
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -225.7% |
| June 30, 2026 | -153.3% |
| March 31, 2026 | -882.4% |
| December 31, 2025 | -22.72% |
| September 30, 2025 | -333.0% |
| June 30, 2025 | -1.49K% |
| March 31, 2025 | -1.63K% |
| December 31, 2024 | -148.3% |
| September 30, 2024 | -101.9K% |
| June 30, 2024 | -13.18K% |
| March 31, 2024 | -5.46K% |
| December 31, 2023 | -31.43% |
| September 30, 2023 | -843.7% |
| June 30, 2023 | -1.40K% |
| March 31, 2023 | -497.8% |
| December 31, 2022 | -929.3% |
| September 30, 2022 | -132.7K% |
| June 30, 2022 | -840.2% |
| March 31, 2022 | -746.0% |
| December 31, 2021 | -332.3% |
| September 30, 2021 | -630.7% |
| June 30, 2021 | -14.58K% |
| March 31, 2021 | -872.9% |
| Date | Value |
|---|---|
| December 31, 2020 | -547.3% |
| September 30, 2020 | 12.44% |
| June 30, 2020 | -219.3% |
| March 31, 2020 | -659.2% |
| December 31, 2019 | -307.5% |
| September 30, 2019 | -856.1% |
| June 30, 2019 | -1.45K% |
| March 31, 2019 | -1.41K% |
| December 31, 2018 | -409.4% |
| September 30, 2018 | -105.0% |
| June 30, 2018 | -525.3% |
| March 31, 2018 | -787.9% |
| December 31, 2017 | -986.9% |
| September 30, 2017 | -423.4% |
| June 30, 2017 | -853.7% |
| March 31, 2017 | -4.56K% |
| December 31, 2016 | -4.38K% |
| September 30, 2016 | -2.19K% |
| June 30, 2016 | -562.0% |
| March 31, 2016 | -2.20K% |
| December 31, 2015 | -1.60K% |
| September 30, 2015 | -1.11K% |
| June 30, 2015 | -28.49K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | -- |
| Vertex Pharmaceuticals, Inc. | 19.01% |
| Recursion Pharmaceuticals, Inc. | -641.6% |
| Halozyme Therapeutics, Inc. | 50.11% |
| Novavax, Inc. | -45.94% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -153.7% |
| Return on Assets | -36.32% |
| Return on Invested Capital | -59.75% |
| Gross Profit Margin (Quarterly) | 96.29% |
| Operating Margin (Quarterly) | -234.3% |
| Return on Net Operating Assets | -284.4% |